China $642 Million Nasdaq-Listed Biopharmaceutical & COVID-19 Vaccine Company Sinovac Biotech with $19.4 Billion Revenue in 2021 Receives Nasdaq Conditional Approval to Maintain Public Listing by Filing Annual Report for 2024 & Interim Financial Statements for 2025 Q2, Market Value at $642 Million, Founded in 1993 by Yin Weidong

Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets? Caproasia - Learn more

Caproasia Access | Events | Summits | Register Events | The Financial Centre
The 2026 Investment Day | 2026 Family Office Summits | Family Office Circle

This site is for accredited investors, professional investors, investment managers and financial professionals only. You should have assets around $3 million to $300 million or managing $20 million to $30 billion.

---

China $642 Million Nasdaq-Listed Biopharmaceutical & COVID-19 Vaccine Company Sinovac Biotech with $19.4 Billion Revenue in 2021 Receives Nasdaq Conditional Approval to Maintain Public Listing by Filing Annual Report for 2024 & Interim Financial Statements for 2025 Q2, Market Value at $642 Million, Founded in 1993 by Yin Weidong

25th January | Hong Kong

China Nasdaq-listed biopharmaceutical & COVID-19 caccine company Sinovac Biotech (Pre-suspended $642 million market value) with $19.4 billion revenue in 2021 has received Nasdaq conditional approval to maintain Nasdaq public listing by filing annual report for 2024 & interim financial statements for 2025 Q2.  Sinovac Biotech pre-suspended market value at $642 million.  Sinovac Biotech was founded in 1993 by Yin Weidong.  Sinovac Biotech – Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.  The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.  SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu®), the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.  Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.  With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

“ China $642 Million Nasdaq-Listed Biopharmaceutical & COVID-19 Vaccine Company Sinovac Biotech with $19.4 Billion Revenue in 2021 Receives Nasdaq Conditional Approval to Maintain Public Listing by Filing Annual Report for 2024 & Interim Financial Statements for 2025 Q2, Market Value at $642 Million, Founded in 1993 by Yin Weidong “

- Article continues below -

Quick Links, Ads & Announcements
Caproasia Access | Events | Summits | Register Events | The Financial Centre
The 2026 Investment Day | 2026 Family Office Summits | Family Office Circle

Intelligence at your fingertips
Get Started ($29 per year) : Click here
Caproasia Subscription ($680 yearly | $70 monthly): Click here

The 2026 Investment Day
Hong Kong | Singapore
March / July / Sept / Oct / Nov
Private Equity, Hedge Funds, Boutique Funds, Private Markets & more. Join 20+ CIOs & Senior investment team, with > 60% single family offices with $300 million AUM. Taking place in Hong Kong and in Singapore. Every March, April, July, Sept, Oct & Nov.
Visit | Register here

The 2026 Family Office Summit
9th / 16th April & 15th Oct Hong Kong Ritz Carlton | 23rd / 30th April & 5th Nov Singapore Amara Sanctuary Resort
Join 60 single family offices & family office professionals in Hong Kong & Singapore
Links: 2026 Family Office Summit | Register here

2026 Investment / Alternatives Summit
March / Oct / Nov in Hong Kong & Singapore
Join leading asset managers, hedge funds, boutique funds, private equity, venture capital & real estate firms in Hong Kong, Singapore & Asia-Pacific at the Investment / Alternatives Summit. Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here

2026 Private Wealth Summit
April / Oct / Nov in Hong Kong & Singapore
Join CEOs, CIOs, Head of Private Banking, Head of Family Offices & Product Heads at The Private Wealth Summit.  Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here

China $642 Million Nasdaq-Listed Biopharmaceutical & COVID-19 Vaccine Company Sinovac Biotech with $19.4 Billion Revenue in 2021 Receives Nasdaq Conditional Approval to Maintain Public Listing by Filing Annual Report for 2024 & Interim Financial Statements for 2025 Q2, Market Value at $642 Million, Founded in 1993 by Yin Weidong/b>

Managing $20 million to $3 billion. Investing $3 million to $300 million.
For Investment Managers, Hedge Funds, Boutique Funds, Private Equity, Venture Capital, Professional Investors, Family Offices, Private Bankers & Advisors, sign up today. Subscribe to Caproasia and receive the latest news, data, insights & reports, events & programs daily at 2 pm.

Join Events & Find Services
Join Investments, Private Wealth, Family Office events in Hong Kong, Singapore, Asia-wide. Find hard-to-find $3 million to $300 million financial & investment services at The Financial Centre | TFC. Find financial, investment, private wealth, family office, real estate, luxury investments, citizenship, law firms & more.  List hard-to-find financial & private wealth services.

Have a product launch? Promote a product or service? List your service at The Financial Centre | TFC. Join interviews & editorial and be featured on Caproasia.com or join Investments, Private Wealth, Family Office events. Contact us at [email protected] or [email protected]

Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets?

Quick Links

Caproasia Access | Events | Summits | Register Events | The Financial Centre
The 2026 Investment Day | 2026 Family Office Summits | Family Office Circle

Web links may be disabled on mobile for security.
Please click on desktop.

---

New to Caproasia
Learn More | Sign Up | Subscribe | Register Events

Caproasia Users

• Manage $20 million to $30 billion of assets
• Invest $3 million to $300 million
• Advise institutions, billionaires, UHNWs & HNWs

Caproasia Platforms | 11,000 Investors & Advisors

• Caproasia.com
• Caproasia Access
• Caproasia Events
• The Financial Centre | Find Services
• Membership
• Family Office Circle
• Professional Investor Circle
• Investor Relations Network

Monthly Roundtable & Networking

• Professional Investor
• Family Office
• HNW Partnership

Family Office Programs

• Family Office Circle
• Family Office Networking
• Family Office Roundtable
• The Family Office Summit

The 2026 Investment Day

• March - Hong Kong
• March - Singapore
• April - Hong Kong
• April - Singapore
• July - Hong Kong
• July - Singapore
• Sept- Hong Kong
• Sept - Singapore
• Oct- Hong Kong
• Nov - Singapore
• Visit: The Investment Day | Register: Click here

Caproasia Summits

• The Institutional Investor Summit
• The Investment / Alternatives Summit
• The Private Wealth Summit
• The Family Office Summit
• The CEO & Entrepreneur Summit
• The Capital Markets Summit
• The ESG / Sustainable Investment Summit

Contact Us

For Enquiries, Membership
[email protected], [email protected]

For Listing, Subscription
[email protected], [email protected]

For Press Release, send to:
[email protected]

For Events & Webinars
[email protected]

For Media Kit, Advertising, Sponsorships, Partnerships
[email protected]

For Research, Data, Surveys, Reports
[email protected]

For General Enquiries
[email protected]

---

Caproasia | Driving the future of Asia
a financial information technology co.
since 2014

---